Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

March 2018

Brian Lyons, Department of Oncology
Use of a mirror image D-amino acid peptide shield to induce immune silencing of an oncolytic virus rendering it hidden to pre-existing neutralising antibodies thus increasing bio-availability and therapeutic efficacy

Abirami Lakshminarayanan, Radiobiology Research Institute, Department of Oncology
Antibody fragments as next generation imaging probes for radiation therapy

Felix Clanchy, Kennedy Institute of Rheumatology
How do IRAK-3 Isoforms contribute to tumour progression?

Akane Kawamura, Department of Chemistry
Targeting the NSD family protein methyltransferases for cancer treatment

Lisa Heather, Department of Physiology, Anatomy and Genetics
Fatty acids as novel metabolic regulators of HIF signalling and hypoxic sensitivity in cancer

Fiona Bangs, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology and The Kennedy Institute of Rheumatology
The impact of the primary cilium on initiation and progression of pancreatic ductal adenocarcinoma

Serena Lucotti, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology
Targeting tumour cell transendothelial migration during metastasis

Richard Bryant, Nuffield Department of Surgical Sciences
Transcriptomics of pre-radiotherapy prostate cancer biopsy samples – a “proof-of-concept” study

Audrey Gerard, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences and The Kennedy Institute of Rheumatology
Increasing cancer vaccine efficacy through temporal blockade of IFNg

Peter Holland, Department of Zoology
Assessment of novel Testicular Germ Cell Tumour markers

Adam Cribbs, Botnar Research Centre – Oxford Centre for Translational Myeloma Research
Identifying epigenetic targets to modulate immune checkpoints in the treatment of multiple myeloma

Tim Humphrey, CRUK-MRC Oxford Institute for Radiation Oncology, Department of Oncology
Binding partners and imaging of the p53-targeting agent RITA

Simon Aldridge, Department of Chemistry
Novel boron-containing 18F tags for PET and bimodal imaging

Hagen Schwenzer, Department of Oncology
Exploring LARP6 as new potential drug target to treat HER2-negative gastric cancer